Advancing our pipeline

Our expanding pipeline of Probody® therapeutics is built on a robust portfolio of proprietary and patented technology. Rooted in innovation and differentiation, and driven by our vision and mission, we are advancing a deep oncology pipeline of Probody therapeutics through our own bold science and partnerships with some of the world’s leading biopharmaceutical companies.

Research & development

Product Candidate
Target
Indication
Preclinical
Phase 1
Phase 2
Partner

Wholly-Owned or Retained US Rights*

❯ CX-904
EGFRxCD3
Solid Tumors
CytomX Therapeutics Amgen
❯ CX-2051
EpCAM
Solid Tumors
CytomX Therapeutics
❯ CX-801
IFN-α2b
Solid Tumors
CytomX Therapeutics
Probody TCBs
Undisclosed
TBD
CytomX Therapeutics Astellas

*U.S. Rights include wholly-owned molecules or collaboration molecules in which CytomX has a right or option to share in U.S. commercial profits

Fully Partnered Pipeline

Probody TCBs
Undisclosed
TBD
Amgen Astellas Regeneron
Various
Undisclosed
TBD
Bristol Myers Squibb
Various
Undisclosed
Oncology & Non-Oncology
Moderna
Probody® Modality:
ADCs
TCBs
mRNA
Immunotherapy
Undisclosed

Lead candidates

We are utilizing our Probody® platform to develop potential best-in-class therapies against clinically validated targets and potential first-in-class therapeutics against novel, difficult-to-treat targets.

We believe our Probody therapeutics have the potential to:

  • Create or widen therapeutic window – the balance between a therapy’s dose that is effective without causing unacceptable toxicity
  • Enable new combinations of drugs previously not possible due to toxicities
  • Expand the universe of viable therapeutic targets by opening “undruggable” target space
  • Make new treatment options possible for more patients

CX-904
(EGFRc-CD3 conditionally activated T cell engaging bispecific)

CytomX and Amgen are developing CX-904, a T-cell-engaging bispecific Probody candidate against the epidermal growth factor receptor (EGFR) on cancer cells and the CD3 receptor on T cells. The drug candidate is currently in a Phase 1 dose-escalation study in patients with advanced solid tumors.

CX-2051
(EpCAM-directed conditionally activated antibody-drug conjugate)

CX-2051 is a wholly-owned conditionally activated ADC directed toward the epithelial cell adhesion molecule (EpCAM), with potential applicability across multiple EpCAM-expressing epithelial cancers. EpCAM is a validated anti-cancer target for which systemic therapies not yet been developed due to widespread expression on normal tissues. CX-2051 is designed to open a therapeutic window for a systemically administered anti-EpCAM ADC. The drug candidate is currently in a Phase 1 dose-escalation study in patients with advanced solid tumors.

CX-801
(Interferon alpha-2b Probody cytokine)

CX-801 is a wholly-owned interferon (IFN) alpha-2b Probody. Interferons are approved anti-cancer therapies but are limited by narrow therapeutic windows. Based on preclinical studies, CX-801 demonstrated a wide therapeutic index with an enhanced tolerability profile versus unmasked IFN, without compromising its potent antitumor effects. CX-801 has broad potential applicability in traditionally immuno-oncology sensitive as well as
insensitive (cold) tumors

Clinical trials

Several of our most promising drug candidates are currently in clinical trials, investigating their potential utility in a number of advanced or recurrent cancers.

Learn More

Access information for healthcare providers & patients

Learn More